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ABSTRACT: The hematocrit-bias still remains one of the
most discussed issues when it comes to dried blood spot
(DBS) analysis. Therefore, many attempts to cope with this
issue have been made, among which the development of novel
sampling tools such as the Capitainer-B (further referred to as
MF (microﬂuidic)-DBS) devices. These are designed to allow
a straightforward absorption of a ﬁxed volume (13.5 μL) of
blood by a preperforated paper disc, which can be analyzed
afterward. The aim of this study was to evaluate the potential
of these devices to nullify the hematocrit-based area bias and
to investigate whether the amount of blood applied has an
inﬂuence on the device performance. An LC-MS/MS method
for the quantiﬁcation of caﬀeine and paraxanthine in MF-DBS
was fully validated, meeting all preset acceptance criteria. In a next step, using a set of 133 authentic, venous patient samples
with a hematocrit range of 18.8−55.0, concentrations of both compounds in MF-DBS were compared to those in corresponding
partial-punch pipetted DBS (PI-DBS) and liquid blood samples. When compared to blood as a reference, the concentrations
obtained in MF-DBS were not aﬀected by a bias in function of the evaluated hematocrit, in contrast to those obtained from
partial-punch PI-DBS. Furthermore, analysis of samples resulting from spiking diﬀerent volumes of whole blood at diﬀerent
hematocrit levels, revealed that the amount of blood applied at the device inlet has no inﬂuence on the performance of the
devices. Therefore, it can be concluded from this study, being the ﬁrst in which the impact of the hematocrit and the applied
volume is evaluated by analyzing authentic, venous patient samples, that MF-DBS devices eﬀectively assist in eliminating the
hematocrit-based area bias, independently from the applied blood volume.
Lately, many eﬀorts have been made in an attempt toovercome the well-discussed hematocrit (Hct)-issue
coupled to classical dried blood spot (DBS) analysis.
Theoretically, the overall Hct-based bias can be seen as a 3-
fold problem, that is, a distinction can be made between a Hct-
based area bias, a Hct-based recovery bias, and a Hct-based
matrix bias.1 The Hct-based recovery bias is resulting from the
fact that the internal standard is typically only added during the
extraction step for conventional DBS extraction, leading to the
inability to correct for variations in recovery from the dried
blood. Furthermore, a Hct-based matrix bias can be the result
of the fact that a DBS sample with a diﬀerent Hct can be
considered as being a diﬀerent matrix. Therefore, for the
evaluation of recovery and matrix eﬀects during method
validation, the inclusion of blood samples with a broad Hct
range is very valuable. The Hct-based area bias is best
documented and is the consequence of the diﬀerent spreading
of whole bloodwith a varying Hctover classical DBS cards
because of diﬀerences in the viscosity of the blood: blood with
a higher Hct (e.g., 50%) will spread less compared to the same
amount of blood with a lower Hct (e.g., 30%). This
phenomenon gives rise to DBS with a substantially diﬀerent
area, which in turn leads to a diﬀerence in the amount of
analyte sampled when using a ﬁxed diameter subpunch.
Logically, a whole spot analysis after volumetric application of
a ﬁxed amount of blood should nullify this area bias. However,
volumetric application can only be achieved when using a
dedicated device.
Volumetric application by using anticoagulant-coated micro-
capillaries or calibrated pipettes will in clinical practice only be
possible in situations where dedicated staﬀ (e.g., an
experienced nurse or trained laboratory personnel) is available
(e.g., patients in a hospital setting, post-mortem sampling or
preclinical studies).2 When this volumetric application needs
to be performed by nonexperienced people (e.g., patients at
home), this nondirect application of a drop of blood
constitutes a non-negligible disadvantage. Therefore, to render
volumetric dried blood sampling at home possible, diﬀerent
strategies have been proposed to volumetrically generate the
dried samples, without the necessity of using a calibrated pipet.
The HemaPEN technology (Trajan Scientiﬁc and Medical,
Australia), the volumetric absorptive microsampling (VAMS)
technology (Neoteryx, USA), the volumetric absorptive paper
disc (VAPD), mini-disc (VAPDmini), and the HemaXis DB
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device (DBS System SA, Gland, Switzerland) are examples of
techniques proposed for a user-friendly generation of
volumetric dried blood samples.3−9 However, although direct
application of a blood drop from a ﬁngertip onto the above-
mentioned devices may be relatively straightforward, proper
instructions still need to be given to self-sampling patients in
order to avoid incorrect sampling, leading to erroneous results.
Here, we focus on the Capitainer-B (further referred to as MF
(microﬂuidic)-DBS) device, recently designed by the KTH
Royal Institute of Technology (KTH, Stockholm, Sweden)
and commercialized by Capitainer AB (Stockholm, Sweden).
The device is equipped with an inlet port to which a drop of
blood (e.g., obtained via a ﬁngerprick) is added, resulting in
the ﬁlling of a capillary microchannel with a ﬁxed volume of
13.5 μL. Upon completely ﬁlling this capillary channel, a thin
ﬁlm at the inlet dissolves, resulting in the absorption of the
excessive amount of blood by a paper matrix, leading to the
separation of the excess blood and the ﬁlled channel. Finally,
upon dissolving of a thin ﬁlm at the outlet, the capillary
channel is emptied through capillary forces, resulting in the
absorption of 13.5 μL of blood by a preperforated paper disc
(Ahlstrom 222 ﬁlter paper).10 Spooner et al. readily provided a
proof of concept in which it was demonstrated that the devices
are able to precisely dispense an average blood volume of 13.5
μL across an artiﬁcially generated broad Hct range (25−
65%).11 Furthermore, a good agreement was found when
comparing the results of the MF-DBS devices with those of
liquid whole blood, making use of the direct alcohol marker
phosphatidylethanol 16:0/18:1.12 On the basis of these proof
of concepts, the MF-DBS devices show promise to overcome
the Hct-based area bias, while maintaining the beneﬁts coupled
to classical DBS analysis. However, although for phosphatidy-
lethanol 16:0/18:1 determinations, authentic, venous patient
samples were used, no information was provided on the Hct
levels of the used patient samples, meaning that no conclusion
could be made on the ability of the MF-DBS devices to
overcome the Hct bias. Therefore, the impact of the Hct on
the analysis of authentic patient samples remained to be
established. Furthermore, it remained to be investigated
whether the amount of blood dispensed at the device inlet
has an impact on the accuracy and precision. Therefore, the
aim of this study was to evaluate the potential of MF-DBS
devices to eliminate the Hct-based area bias by analyzing 133
left-over patient samples across a wide Hct range (18.8−55.0),
with caﬀeine and paraxanthine as model compounds. To do so,
concentrations measured in MF-DBS were compared to
corresponding whole blood and partial-punch pipetted DBS
(PI-DBS). Moreover, diﬀerent volumes of blood (25, 30, 35,
40, and 50 μL) were applied, originating from patient samples
with a very low or very high Hct to check whether the amount
of blood added at the inlet port has an inﬂuence on the
performance of the devices. Since the included samples
originated from patients admitted to 17 hospital departments
(including surgery, radiology, rheumatology, endocrinology,
and nephrology, among others), the samples used in this study
include a wide variety of characteristics, which is highly
relevant to assess the device’s practical relevance and
robustness.
■ EXPERIMENTAL SECTION
Chemicals and Stock Solutions. Formic acid, caﬀeine,
paraxanthine, and the internal standards (IS) caﬀeine-13C3 and
paraxanthine-13C4-
15N3 were obtained from Sigma-Aldrich
(Diegem, Belgium). LC-MS grade methanol was purchased
from Biosolve (Valkenswaard, The Netherlands). A Synergy
Water Puriﬁcation System (Merck Millipore, Overijse,
Belgium) provided ultrapure water. For caﬀeine and para-
xanthine, stock solutions of 1 mg/mL were prepared by
dissolving 10 mg of the compound in 10 mL of water. For the
IS, an appropriate dilution of a commercially available 1 mg/
mL solution of caﬀeine-13C3 in methanol and a dilution of 2
mg of paraxanthine-13C4−15N3 in 20 mL of methanol provided
a 100 μg/mL stock solution. Working solutions of the
standards and the IS were prepared on the day of analysis by
diluting the stored (−20 °C) stock solutions with water.
Independently prepared stock solutions were used to prepare
the calibrators and quality control samples (QCs) as described
before.13
Sample Collection. Blank venous whole blood from a
caﬀeine abstinent healthy, female volunteer was collected in
EDTA tubes (BD Vacutainer with BD Hemogard closure 10
mL) and used for the preparation of calibrators and QC
samples. Whole blood samples were generated by transferring
50 μL of blood into 2 mL Eppendorf tubes. MF-DBS devices
were generously provided by Capitainer AB (Stockholm,
Sweden). MF-DBS were generated by pipetting 35 μL of
whole blood at the inlet port of the device using a calibrated
pipet. After completing sampling, the devices were left to dry
for approximately 3 h at room temperature prior to storage at
ambient temperature in the presence of desiccant (two 5 g
Minipaxabsorbent packets, Sigma-Aldrich) in zip-closure
plastic bags until analysis. PI-DBS were prepared by pipetting
25 μL of whole blood onto Whatman 903 ﬁlter paper (GE
Healthcare, Dassel, Germany) using a calibrated pipet. The
drying conditions were the same as described above for the
MF-DBS.
When necessary, a Sysmex XE-5000 hematology analyzer
(Sysmex Corp., Kobe, Japan) was used to determine the
(adapted) Hct.
Sample Preparation and UPLC-MS/MS Method. For
the MF-DBS, sample preparation was performed by removing
the preperforated paper discs using tweezers and transferring
these into 2 mL Eppendorf tubes, before adding 225 μL of a
methanol/water (80/20, v/v) mixture, containing 0.01%
formic acid and both labeled IS, at 33 ng/mL and 16.5 ng/
mL for caﬀeine-13C3 and paraxanthine-
13C4-
15N3, respectively.
Subsequently, the samples were shaken for 10 min at 1000 rpm
and 60 °C on a Thermoshaker TS-100C (BioSan, Riga,
Latvia), followed by a centrifugation step at ambient
temperature for 10 min at 10 000g. Before injection of 10 μL
onto the UPLC column, 90 μL of the supernatant was diluted
with 550 μL of water, containing 0.01% formic acid of which
250 μL was transferred to a vial with plastic insert. For
quantiﬁcation of caﬀeine and paraxanthine in PI-DBS (What-
man 903 ﬁlter paper) and whole blood samples, readily
available fully validated methods were used, with a central 3
mm punch being used for PI-DBS.13
A Waters Acquity UPLC system (Waters, Milford, MA,
USA) coupled to a SCIEX API 4000 mass spectrometer
(SCIEX, Framingham, MA, USA) was used to analyze all
samples. The LC-MS/MS system was controlled by SCIEX
analyst 1.6.2 and by the Waters Acquity console software.
Mobile phases A and B consisted of 0.01% formic acid in water
and methanol, respectively. The same chromatography and
mass spectrometry parameters as described elsewhere were
used for the analysis of PI-DBS, whole blood, and MF-DBS.13
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Validation of the MF-DBS Method. Method validation
was based on U.S. Food and Drug Administration (FDA) and
European Medicines Agency (EMA) guidelines for bioanalyt-
ical method validation14,15 and included the evaluation of
accuracy, precision, carry-over, selectivity, homoscedasticity,
calibration model, stability, matrix eﬀect, recovery, and Hct
eﬀect. At the start of each series, control blanks (i.e., MF-DBS
prepared with blank blood and analyzed without IS in the
extraction solvent) and zero samples (i.e., MF-DBS prepared
with blank blood and extracted using the regular solvent) were
analyzed.
Accuracy and precision were determined by analyzing QCs
at four concentration levels (lower limit of quantiﬁcation
(LLOQ), low, mid, and high) in duplicate on three diﬀerent
days. The used concentration levels for caﬀeine and para-
xanthine, respectively, were 0.05 and 0.025 μg/mL (LLOQ),
0.12 and 0.06 μg/mL (low), 4.0 and 2.0 μg/mL (mid), and 8.0
and 4.0 μg/mL (high). The within day and total assay
precision (%relative standard deviation, %RSD) were deter-
mined by using a single factor analysis of variance (ANOVA),
while the accuracy (%bias) was evaluated by dividing the
diﬀerence between the obtained concentration and the
nominal value by the nominal value, this multiplied by
100.16,17 Both, the %bias and the %RSD should be within
±15%, except for the LLOQ (within ±20%).15
Carry-over was assessed by injecting 2 blank samples after
the highest calibrators, on four diﬀerent days (n = 8). Carry-
over is considered acceptable when the obtained responses for
the analytes were less than 20% of the LLOQ peak area and
less than 5% for the IS.15 For selectivity, identical acceptance
criteria were applied. Selectivity was evaluated by analyzing
blank MF-DBS, prepared with whole blood originating from 8
diﬀerent volunteers.
Eight-point calibration lines were measured in duplicate on
each of 4 days to evaluate homoscedasticity and the calibration
model. The nominal concentrations of the calibrators were
0.050, 0.10, 0.25, 0.50, 1.0, 2.5, 5.0, and 10.0 μg/mL for
caﬀeine and 0.025, 0.050, 0.10, 0.25, 0.50, 1.0, 2.5, and 5.0 μg/
mL for paraxanthine. An F-test (α = 1%) at the lowest and
highest calibrators was used to test the homoscedasticity.
Furthermore, both unweighted and weighted (1/x, 1/x2, 1/
√x, 1/y, 1/y2, and 1/√y) linear and quadratic regression were
applied to ﬁnd the best ﬁtting model. The sum% relative error
(RE) and plotting of the %RE against the nominal
concentrations was used to compare the obtained models. A
back-calculation, in which the mean concentrations of the
calibrators should be within ±15% of the nominal value or
within ±20% for the LLOQ, was performed before accepting a
selected model.15
Former experiments did not reveal any problems with the
(processed sample) stability of caﬀeine and paraxanthine.5,13
However, since the DBS paper included within the MF-DBS
device is not completely identical to the paper used within the
previously validated PI-DBS method, a limited stability study
was carried out here. Stability was assessed by analyzing low
and high QCs in triplicate after 4 days of storage at 60 °C and
after 3 months of storage at −20 °C and at room temperature
in zip-closure plastic bags containing two 5 g packages of
desiccant. A freshly prepared eight-point calibration line was
used at each day of analysis to calculate the concentration of
the stored MF-DBS. To be acceptable, the mean concentration
of the QCs at a particular time point should not deviate more
than ±15% from the nominal value.15
Two concentration levels (low or high QC) together with
the IS were spiked to a blank blood extract (originating from 7
diﬀerent donors) (A) or to a neat MeOH/H2O (80/20, v/v) +
0.01% formic acid solution (B) to investigate the matrix eﬀects.
Furthermore, the Hct range was broadened by adding or
removing a speciﬁc amount of plasma from whole blood, this
by centrifuging an aliquot of blood with a Hct of 38.7 in an
Eppendorf 5804R centrifuge (Hamburg, Germany) for 5 min
at 1000g. In this way, 10 diﬀerent blank blood extracts could be
obtained with a Hct ranging from 24.4 to 50.5. The IS-
corrected matrix eﬀect is calculated as the ratio of the peak
areas of (A) to those of (B), multiplied by 100. Overall, the %
RSD of this IS-corrected matrix eﬀect should be less than
15%.15
The recovery was evaluated for low and high QCs (n = 6) at
three diﬀerent Hct levels (target values at 21.0, 42.0, and 62.0),
prepared by adding or removing a certain amount of plasma
from whole blood with a Hct of 40.3. Two sets of MF-DBS
were compared: (C) MF-DBS obtained by pipetting 13.5 μL of
spiked blood directly onto the preperforated paper discs and
(D) MF-DBS generated by pipetting 13.5 μL of blank whole
blood and to which the analytes were only spiked after the
extraction. The average of the peak area of (C) divided by that
of (D) multiplied by 100, revealed the absolute recovery values
(%).
Where relevant, statistical analyses were performed using the
Minitab software.
Application. To get a complete view on the performance
of the MF-DBS devices, a comparative study between MF-
DBS, partial-punch PI-DBS and whole blood samples was
carried out. Caﬀeine and paraxanthine concentrations were
determined in 133 hospital patient blood samples (collected in
EDTA tubes). Approval for this study (the use of left-over
venous blood samples from patients and control blank blood
samples from volunteers) was provided by the Ethics
Committee of Ghent University Hospital (EC2018/0519).
Blank blood, from a single donor (Hct 46.2), was used to
prepare matrix-matched calibration curves. The impact of the
Hct on the MF-DBS and PI-DBS results was evaluated by
plotting the percentage diﬀerence between MF-DBS or PI-
DBS and whole blood in function of the diﬀerent Hct levels.
The diﬀerences between MF-DBS or PI-DBS and whole blood
concentrations, divided by the whole blood concentrations,
multiplied by 100, represented these percentage diﬀerences.
Furthermore, Medcalc statistical software, version 14.12.0
(Medcalc Software bvba., Ostend, Belgium), was used to create
Bland−Altman plots to compare MF-DBS and whole blood
samples.
Additionally, to check whether the amount of blood added
at the inlet port of the device has an inﬂuence on the measured
caﬀeine and paraxanthine concentrations, diﬀerent volumes
(25, 30, 35, 40, and 50 μL) of blood, originating from patient
samples with a very low or high Hct, were applied.
Furthermore, to better reﬂect realistic conditions, the use of
capillary blood (collected via a ﬁngerprick), obtained from 4
healthy volunteers, was tested. Here, a comparison was made
between the caﬀeine and paraxanthine concentrations obtained
via the use of MF-DBS devices with those in liquid capillary
blood. A BD Microtainer contact activated safety lancet (BD,
Franklin Lakes, USA) was used to perform the ﬁngerprick.
Approval for this study was provided by the Ethics Committee
of Ghent University Hospital (EC2018/0519) and a written
informed consent was obtained from each volunteer.
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■ RESULTS AND DISCUSSION
Method Validation. As can be concluded from Table 1,
the overall %bias was below 6.15%, meeting the acceptance
criterion for accuracy. Furthermore, with a within day and total
assay precision (%RSD) below 12%, the acceptance criterion
for precision was also met for both compounds.
No carry-over was found when injecting 2 blank samples
after the highest calibrators. For selectivity, no unacceptable
interferences were observed in blank MF-DBS, prepared with
whole blood from 8 diﬀerent volunteers (Hct range: 37.1−
43.1).
Calibration data for both caﬀeine and paraxanthine were
found to be heteroscedastic. For both compounds, weighted
regression did improve the %RE, therefore weighted linear
regression was selected, using a weighting factor 1/x2. When
using these models, the mean back-calculated concentrations
did not diﬀer more than ±10%. Hence, a linear calibration
model could be accepted for both compounds.
As can be concluded from Table 2, both caﬀeine and
paraxanthine were stable for at least 4 days in MF-DBS when
stored at 60 °C (representing an accelerated stability
experiment) and for at least 3 months when stored at room
temperature or −20 °C.
As displayed in Table 3, the values for the analyte matrix
eﬀect indicate a relevant (>15%) ionization enhancement for
paraxanthine. However, since the IS-corrected matrix eﬀect
was within 98.9−107.1% for both compounds, it can be
concluded that the IS compensates for the diﬀerences in
ionization. Furthermore, the preset acceptance criterion (<15%
%RSD) for the IS-corrected matrix eﬀects was met.
To evaluate the recovery, low and high QCs (n = 6) were
prepared in blank blood with three diﬀerent Hct levels (21.5,
40.7, and 58.3), which was used to generate MF-DBS. High
recovery values were obtained for both compounds, at 105.97
± 3.48% for caﬀeine and 97.36 ± 9.06% for paraxanthine, these
values corresponding to the averages calculated from all values
obtained at all Hct levels and at both QC levels. Furthermore,
when the 40.7 Hct level is normalized to 100%, all recoveries
were within ±15% of this 40.7 Hct reference sample,
demonstrating that the Hct has no statistical signiﬁcant eﬀect
(p > 0.1, one-way ANOVA test) on the recovery (Figure 1).
This conﬁrms the Hct-independence of the MF-DBS devices,
as also observed by Spooner et al., who evaluated the recovery
of radiolabeled material.11
Application. The validated method was applied on 133
authentic, venous left-over patient samples with a Hct ranging
Table 1. Within Day and Total Precision and Accuracy (n = 3 × 2) for QCs of Caﬀeine and Paraxanthine at Four
Concentration Levels (LLOQ, Low, Mid, and High) in MF-DBS
within day precision (%RSD) (n = 3 × 2) total precision (%RSD) (n = 3 × 2) accuracy (%bias) (n = 3 × 2)
QC caﬀeine paraxanthine caﬀeine paraxanthine caﬀeine paraxanthine
LLOQ 6.40 9.42 11.88 9.42 −1.03 3.13
low 3.07 3.69 3.31 4.35 1.67 6.14
mid 3.35 7.48 3.35 7.80 2.92 1.92
high 7.39 5.16 8.84 5.37 4.54 5.92
Table 2. Stability Data for Caﬀeine and Paraxanthine in MF-DBS at Low and High QC (n = 3)a
4 days at 60 °C (%diﬀerence) (n = 3) 3 months at −20 °C (%diﬀerence) (n = 3) 3 months at RT (%diﬀerence) (n = 3)
QC caﬀeine paraxanthine caﬀeine paraxanthine caﬀeine paraxanthine
low 3.33 8.00 7.78 12.39 15.28 14.94
high 7.17 13.5 7.54 0.33 5.04 −0.25
aData are presented as the percentage diﬀerence between the concentration measured at the speciﬁc time points and the nominal values.
Table 3. Analyte Matrix Eﬀect and IS-Corrected Matrix
Eﬀect for Caﬀeine and Paraxanthine
caﬀeine paraxanthine
low QC high QC low QC high QC
analyte matrix eﬀect
mean of 10 donors (%) 98.9 84.9 128.7 115.8
%RSD 4.83 2.27 5.48 2.69
IS-corrected matrix eﬀect
mean of 10 donors (%) 107.1 104.6 105.8 98.9
%RSD 6.80 2.44 6.62 2.10
Figure 1. IS-compensated recovery (%) at low and high QC level (n =
6) for caﬀeine and paraxanthine measured in MF-DBS at 3 diﬀerent
Hct levels (21.5, 40.7, and 58.2), with the 40.7 Hct sample being
normalized to 100%. The full lines indicate the ±15% deviation limits.
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from 18.8 to 55.0, with 35.95 being the median. In 105
respectively 110 of the 133 patient samples (corresponding
MF-DBS, PI-DBS and whole blood samples), caﬀeine and
paraxanthine concentrations were above the respective LLOQs
(0.05 and 0.025 μg/mL). All samples were analyzed against a
calibration curve prepared using blood with a Hct of 46.2. This
relatively high Hct was deliberately chosen, since in this way
the Hct eﬀect on PI-DBS concentrations can be clearly
visualized. Furthermore, it enables to create a worst case
scenario for MF-DBS and PI-DBS, allowing an exhaustive
assessment of (a possible) Hct eﬀect. Figure 2 depicts the
percentage diﬀerence between MF-DBS or PI-DBS concen-
trations and whole blood concentrations in function of the
Hct. Regression lines ﬁtted to the diﬀerences between PI-DBS
and whole blood concentrations had a slope of 0.851 (95% CI;
[0.628−1.08]) and 0.716 (95% CI; [0.480−0.952]) and an
intercept of −43.2 (95% CI; [−51.3 to −35.0]) and −44.3
(95% CI [−52.9 to −35.7]) for caﬀeine and paraxanthine,
respectively, revealing for both compounds a similar Hct-
induced bias, impacting PI-DBS concentrations. PI-DBS
concentrations clearly decreased with a decreasing Hct,
which is in line with previous ﬁndings for both compounds.5,18
In contrast, the concentrations obtained from the MF-DBS
were not aﬀected by a suchlike Hct-eﬀect (Figure 2, lower
panels). The regression lines ﬁtted to the diﬀerences between
the MF-DBS and whole blood concentrations had a slope of
−0.103 (95% CI; [−0.288 to 0.0819]) and −0.0707 (95% CI;
[−0.256 to 0.114]) and an intercept of −1.07 (95% CI; [−7.77
to 5.63]) and −7.92 (95% CI; [−14.7 to 1.18]) for caﬀeine
and paraxanthine, respectively. Incurred sample reanalysis
resulted in regression lines with a slope of 0.00398 (95% CI;
[−0.164 to 0.172]) and −0.00122 (95% CI; [−0.232 to
0.230]) and an intercept of −3.79 (95% CI; [−9.85 to 2.27])
and −2.59 (95% CI; [−11.0 to 5.81]) for caﬀeine and
paraxanthine, respectively. Since the 95% CIs of the slopes for
both compounds, for both analyses, included 0, it can be
concluded that the diﬀerences between the MF-DBS and
whole blood concentrations did not change in function of the
Hct, this within the Hct range of 18.8 to 55.0. Therefore, the
Hct-independence of the devices, as readily suggested by
Spooner et al., who evaluated the recovery of radiolabeled
material, is supported by these ﬁndings on authentic, venous
patient samples.11
Bland−Altman plots for the diﬀerences between MF-DBS
and whole blood concentrations (Figure 3) revealed a mean
negative bias of −5.2% (95% CI; [−6.87 to −3.29%] and
−11.5% (95% CI; [−13.23 to −9.39%]) for caﬀeine and
paraxanthine, respectively. Incurred samples reanalysis revealed
a mean negative bias of −4.0% (95% CI; [−5.47 to −2.42%]
and −3.3% (95% CI; [−5.23 to −1.08%]) for caﬀeine and
paraxanthine, respectively. From this it can be concluded that
in our experiments the concentrations were slightly under-
estimated in MF-DBS versus whole blood. However, taking
into account that results from diﬀerent matrices (i.e., dried
MF-DBS versus liquid whole blood), obtained by diﬀerent
extraction methods and analyzed in separate analytical runs on
diﬀerent days, were compared, it can be concluded that these
deviations were limited. For example, 93.3% and 89.1% of the
caﬀeine and paraxanthine samples, respectively, did not diﬀer
more than 20% from the whole blood concentrations. For the
incurred sample reanalysis, this was the case for 97.1% and
93.6% of the caﬀeine and paraxanthine samples, respectively,
Figure 2. Percentage diﬀerence between MF-DBS or PI-DBS concentrations and whole blood concentrations, plotted against hematocrit for
caﬀeine (n = 105) and paraxanthine (n = 110). Broken lines represent linear regression lines.
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meeting the acceptance criterion for incurred sample
reanalysis.15 Moreover, when comparing the incurred sample
reanalysis to the original MF-DBS analysis, 97 out of the 105
caﬀeine samples, and 90 out of the 110 paraxanthine samples
were within ±20% of the mean, meeting the acceptance
criterion for incurred samples reanalysis.14 Furthermore, the
diﬀerent types of samples were analyzed against calibration
curves prepared in the respective matrices, with accuracy values
(%bias) for QCs of caﬀeine and paraxanthine within ±6% and
±5% (±14% at LLOQ level) for MF-DBS and whole blood
samples, respectively. The storage conditions used during the
actual study (1 day at 4 °C for whole blood samples and 1 day
at room temperature for MF-DBS) did deﬁnitely not exceed
the storage conditions in which both analytes were stable in
both whole blood (stable for at least 7 days at 4 °C) and MF-
DBS devices (stable for at least 3 months when stored at room
temperature).13 Moreover, Hct had no eﬀect on ion
suppression or enhancement for MF-DBS. Therefore, we
believe that a possible explanation for the positive bias
observed in our study may be found in the fact that the
patient samples were analyzed against a calibration curve
prepared from blood with a Hct of 46.2, which was rather high,
since only 15 out of the 133 included patient samples had a
Hct value above 46.2. Although our recovery experiments had
not revealed a Hct-dependent impact on recovery during
method validation, this limited bias could still be induced by a
small diﬀerence in recovery, taking into account that recovery
experiments were performed using a small number (n = 6) of
spiked samples, while here a number of 133 authentic, venous
patient samples were evaluated. As noted earlier, here, we
wished to “stress” the system, by using calibrators set up in a
Hct at the higher end of the normal range, rather than using
calibrators at about the median Hct of the anticipated range, as
we recommend for dried blood analysis.2,19
In reality, samples will be collected by applying an undeﬁned
volume of blood, resulting from a ﬁnger prick, rather than by
pipetting an amount of blood by the help of a calibrated pipet.
We therefore evaluated whether the amount of blood added at
the inlet port of the device inﬂuences the measured analyte
concentrations. To this end, we applied diﬀerent volumes (25,
30, 35, 40, and 50 μL) of blood, originating from authentic,
venous patient samples with a Hct of 18.8, 22.8, 50.1, and 55.
Results are depicted in Figure 4.
When comparing the concentrations obtained by pipetting
diﬀerent volumes, a CV% lower than 6.20% is obtained for
both compounds. Therefore, it can be concluded that the
amount of blood applied at the inlet of the device does not
have an impact on the caﬀeine and paraxanthine concentration
measured, this independent from a patient’s Hct. Lastly, to
exclude that coagulation may pose a problem, a small
preliminary study was set up in which the use of non-
anticoagulated capillary blood (obtained via a ﬁngerprick) was
evaluated. Capillary blood, obtained from 4 healthy volunteers,
was pipetted onto MF-DBS devices and as a reference
measurement, liquid capillary blood obtained from the same
ﬁngerprick was analyzed. In all cases, the diﬀerence between
MF-DBS and capillary liquid blood concentrations was below
±13.5% for both compounds, suggesting that also with
nonanticoagulated blood the speciﬁcations are met. Further,
large-scale, experiments in which the capillary blood is applied
Figure 3. Bland−Altman plots for the comparison between whole
blood and MF-DBS concentrations for caﬀeine (n = 105) and
paraxanthine (n = 110). Mean diﬀerences and limits of agreement
(LoAs) are represented by full lines, 95% conﬁdence limits by broken
lines.
Figure 4. Evaluation of the impact of applying diﬀerent volumes of
blood, originating from patient samples with a Hct of 18.8, 22.8, 50.1
and 55, at the device’s inlet.
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directly onto the devices are necessary to substantiate this
conclusion.
■ CONCLUSION
MF-DBS devices, one of the recently proposed strategies to
help overcoming the Hct-based area bias allow an accurate
collection of a ﬁxed volume (13.5 μL) of blood. In this study,
the potential of the devices to eﬀectively nullify the Hct-based
area bias was evaluated by analyzing 133 samples, prepared
from whole blood covering a wide Hct range (18.8−55.0)
originating from hospital patients. To this end, an LC-MS/MS
method for the quantiﬁcation of caﬀeine and paraxanthine,
making use of MF-DBS devices, was completely validated,
including the evaluation of both bioanalytical and dried blood
sample speciﬁc parameters, with all preset acceptance criteria
being met. Analyte concentrations measured in MF-DBS
samples were compared to those measured in corresponding
partial-punch PI-DBS and liquid whole blood samples. This
comparison revealed that there was no Hct-dependent impact
on the concentrations measured in MF-DBS, in contrast to
parial-punch PI-DBS concentrations. However, we did observe
a limited mean negative bias for both analytes in MF-DBS,
when compared to whole blood. The use of blank blood with a
rather high Hct (46.2) for the preparation of the calibrators
might explain this, although no impact of Hct on recovery was
observed during method validation. Given the results obtained
and pending conﬁrmation by others, using the same or other
analytes, we conclude on the cautious side, that also for the
MF-DBS devices it may be advisable to set up calibration lines
at the anticipated median of the population-to-be-investigated.
Evaluation of a potential volume impact by analyzing caﬀeine
and paraxanthine concentrations in MF-DBS, derived from
patient samples with a very low (18.8 and 20.8) or a very high
(50.1 and 55) Hct, demonstrated that the amount of blood
added at the inlet of the devices has no inﬂuence on the
performance of the device, independently from the blood’s
Hct. Moreover, a preliminary study using capillary blood of 4
healthy volunteers indicated that the use of nonanticoagulated
blood did not cause a problem.
On the basis of these ﬁndings, obtained by applying fully
validated methods on authentic, venous patient samples, we
conclude that the MF-DBS devices eﬀectively assist in
nullifying the Hct-based area basis for caﬀeine and para-
xanthine and that the volume added at the inlet of the device
does not have an impact on the measured analyte
concentrations. It is important that these ﬁndings, which
seem promising, should be corroborated by others, using other
compounds with diﬀerent features. In addition, further
evaluation of the device by using capillary microsamples,
applied directly from a ﬁngertip, is essential for evaluating its
robustness in real practice. The latter is important to accept
MF-DBS devices as a reliable alternative for whole blood
analysis in existing and emerging applications.
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